Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000398528

Medchemexpress LLC Lmp2a (426-434) | 152274-91-4 | 96.1% | 906.16 | 5 MG
SDP

Catalog No. 5000398528
Encompass_Preferred

LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). It can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06, and A*02:07). This peptide induces a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8+ IFN-γ+ T cells. It also induces specific CTLs to effectively kill target cells expressing LMP2A. It is used in the study of EBV-related malignant tumors such as Hodgkin's disease and nasopharyngeal carcinoma.

  • Induces IFN-γ secreting cells at a frequency of 80.6 SFC/5x10⁴ CD8+ T cells (at 20 μg/mL for 24 h).
  • Significantly increases the proportion of CD8+IFN-γ+ cells (at 20 μg/mL for 2 weeks).
  • Specific CTLs effectively kill peptide-pulsed T2 cells and 293T-LMP2A cells (at 20 μg/mL for 4 h).

Catalog No. 50-003-98528 Supplier Medchemexpress LLC Supplier No. HYP54705MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). It can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06, and A*02:07). This peptide induces a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8+ IFN-γ+ T cells. It also induces specific CTLs to effectively kill target cells expressing LMP2A. It is used in the study of EBV-related malignant tumors such as Hodgkin's disease and nasopharyngeal carcinoma.

  • Induces IFN-γ secreting cells at a frequency of 80.6 SFC/5x10⁴ CD8+ T cells (at 20 μg/mL for 24 h).
  • Significantly increases the proportion of CD8+IFN-γ+ cells (at 20 μg/mL for 2 weeks).
  • Specific CTLs effectively kill peptide-pulsed T2 cells and 293T-LMP2A cells (at 20 μg/mL for 4 h).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.